Lundbeck Pharms Llc patents expiration
1. Carnexiv patents expiration
CARNEXIV's oppositions filed in EPO
CARNEXIV Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(4 years from now) | |
| US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(4 years from now) | |
| US7635773 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US8410077 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9750822 | LUNDBECK PHARMS LLC | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
| US9493582 | LUNDBECK PHARMS LLC | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(8 years from now) | |
| US11529357 | LUNDBECK PHARMS LLC | Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine |
Jan, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or gener...
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
CARNEXIV family patents
